AR129504A2 - Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas - Google Patents
Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticasInfo
- Publication number
- AR129504A2 AR129504A2 ARP230101396A ARP230101396A AR129504A2 AR 129504 A2 AR129504 A2 AR 129504A2 AR P230101396 A ARP230101396 A AR P230101396A AR P230101396 A ARP230101396 A AR P230101396A AR 129504 A2 AR129504 A2 AR 129504A2
- Authority
- AR
- Argentina
- Prior art keywords
- dihydrochloride hydrate
- omecamtiv mecarbil
- mecarbil dihydrochloride
- omecamtiv
- crystalline form
- Prior art date
Links
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 title abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 abstract 12
- 229950001617 omecamtiv mecarbil Drugs 0.000 abstract 12
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 229910002483 Cu Ka Inorganic materials 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 239000000945 filler Substances 0.000 abstract 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Hidrato de diclorhidrato de omecamtiv mecarbil. Reivindicación 2: El hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizado porque el hidrato de diclorhidrato de omecamtiv mecarbil es un monohidrato. Reivindicación 3: Una forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizada porque la forma cristalina se caracteriza por un patrón de difracción en polvo de rayos X que comprende picos en 6,6, 14,9, 20,1, 21,4, y 26,8 ± 0,2º 2q utilizando radiación Cu Ka. Reivindicación 7: Una forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizada porque el hidrato de diclorhidrato de omecamtiv mecarbil se caracteriza por un patrón de difracción en polvo de rayos X que comprende picos en 6,6, 8,4, 14,9, 15,4 y 26,8 ± 0,2º 2q utilizando radiación Cu Ka. Reivindicación 10: Una forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizada porque el hidrato de diclorhidrato de omecamtiv mecarbil se caracteriza por un patrón de difracción en polvo de rayos X que comprende picos en 6,6, 14,9, 16,3, 19,5 y 26,8 ± 0,2º 2q utilizando radiación Cu Ka. Reivindicación 12: Una composición farmacéutica caracterizada porque comprende el hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1 o 2, o la forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de conformidad con cualquiera de las reivindicaciones 3 - 11. Reivindicación 13: Una composición farmacéutica caracterizada porque comprende: 6,13 - 18,37% p/p de un hidrato de diclorhidrato de omecamtiv mecarbil; 25 - 30% p/p de un agente de liberación de control, en donde el agente de liberación de control es hidroxipropilmetilcelulosa; 7,66 - 18,37% p/p de un agente de modificación de pH que es ácido fumárico; y 32,27 - 60,21% p/p de un relleno, en donde el relleno es una combinación de celulosa microcristalina y monohidrato de lactosa. Reivindicación 14: La composición farmacéutica de conformidad con la reivindicación 13, caracterizada porque tiene una relación en peso del agente modificador del pH al hidrato de diclorhidrato de omecamtiv mecarbil de menos de 2:1 a 1:1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785763P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129504A2 true AR129504A2 (es) | 2024-09-04 |
Family
ID=50549466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101155A AR095542A1 (es) | 2013-03-14 | 2014-03-14 | Compuestos heterocíclicos y sus usos |
| ARP230101396A AR129504A2 (es) | 2013-03-14 | 2023-06-01 | Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101155A AR095542A1 (es) | 2013-03-14 | 2014-03-14 | Compuestos heterocíclicos y sus usos |
Country Status (42)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507735B2 (en) | 2004-06-17 | 2009-03-24 | Cytokinetics, Inc. | Compounds, compositions and methods |
| PE20151786A1 (es) * | 2013-03-14 | 2015-12-11 | Amgen Inc | Compuestos heterociclicos y sus usos |
| TWI790189B (zh) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| MX379899B (es) * | 2015-06-26 | 2025-03-11 | Cytokinetics Inc | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal |
| SG10202111790YA (en) * | 2017-06-30 | 2021-12-30 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| MA49508B1 (fr) * | 2017-06-30 | 2024-12-31 | Amgen Inc. | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques |
| EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
| PL3594199T3 (pl) | 2018-07-09 | 2020-11-16 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania |
| EP3820851A1 (en) * | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| MX2021001792A (es) * | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| BR112021017962A2 (pt) * | 2019-03-12 | 2021-11-23 | Amgen Inc | Forma cristalina anidra de base livre do composto a, forma cristalina mono-hidratada de base livre do composto a, forma cristalina do composto a e diclorometano, forma cristalina do composto a e nitrometano, forma cristalina do composto a e hexafluoro-2-propanol, cocristal, composição farmacêutica, e, método para tratar insuficiência cardíaca |
| TWI857027B (zh) * | 2019-03-12 | 2024-10-01 | 美商安進公司 | 心肌肌鈣蛋白活化劑之多晶型物 |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041198A4 (en) * | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| JP7696353B2 (ja) * | 2020-02-10 | 2025-06-20 | アムジェン インコーポレイテッド | オメカムチブメカルビル製剤 |
| JP2022039996A (ja) * | 2020-08-26 | 2022-03-10 | アムジエン・インコーポレーテツド | Ｍｃｌ－１阻害剤処方物 |
| EP4243825B1 (en) | 2020-11-12 | 2025-11-12 | Amgen Inc. | Omecamtiv mecarbil for the treatment of heart failure in selected patient groups |
| WO2022177927A1 (en) * | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2788775B1 (fr) | 1999-01-22 | 2001-04-13 | Pf Medicament | Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique |
| EE200200361A (et) | 1999-12-23 | 2003-10-15 | Pfizer Products Inc. | Hüdrogeeli-juhitav ravimi doseerimise vahend |
| GB0124455D0 (en) | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
| WO2003032963A2 (en) | 2001-10-17 | 2003-04-24 | Aventis Pharma Deutschland Gmbh | Method of reducing type 2 diabetes in high risk patients |
| US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| US7507735B2 (en) | 2004-06-17 | 2009-03-24 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007054975A1 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
| PE20070823A1 (es) | 2005-11-15 | 2007-08-09 | Glaxo Group Ltd | Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona |
| AR058347A1 (es) * | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| EP1962852B1 (en) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7639112B2 (en) | 2007-04-25 | 2009-12-29 | Sony Corporation | Fuse device with integrated switch |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| US9492468B2 (en) | 2008-10-03 | 2016-11-15 | Pericor Therapeutics, Inc. | Methods and compositions for treatment of acute heart failure |
| US9253433B2 (en) | 2012-11-27 | 2016-02-02 | International Business Machines Corporation | Method and apparatus for tagging media with identity of creator or scene |
| AU2014240104B2 (en) * | 2013-03-14 | 2018-11-08 | Amgen Inc. | Heterocyclic compounds and their uses |
| PE20151786A1 (es) | 2013-03-14 | 2015-12-11 | Amgen Inc | Compuestos heterociclicos y sus usos |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| MX379899B (es) | 2015-06-26 | 2025-03-11 | Cytokinetics Inc | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal |
| SG10202111790YA (en) | 2017-06-30 | 2021-12-30 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| MA49508B1 (fr) | 2017-06-30 | 2024-12-31 | Amgen Inc. | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques |
| PL3594199T3 (pl) | 2018-07-09 | 2020-11-16 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania |
| EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| MX2021001792A (es) | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| EP4041198A4 (en) | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| JP7696353B2 (ja) | 2020-02-10 | 2025-06-20 | アムジェン インコーポレイテッド | オメカムチブメカルビル製剤 |
| EP4243825B1 (en) | 2020-11-12 | 2025-11-12 | Amgen Inc. | Omecamtiv mecarbil for the treatment of heart failure in selected patient groups |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2014
- 2014-03-14 PE PE2015002000A patent/PE20151786A1/es unknown
- 2014-03-14 RS RS20191313A patent/RS59536B1/sr unknown
- 2014-03-14 CA CA2902646A patent/CA2902646C/en active Active
- 2014-03-14 KR KR1020227007907A patent/KR102474467B1/ko active Active
- 2014-03-14 EP EP14719472.4A patent/EP2968173B1/en active Active
- 2014-03-14 MA MA38399A patent/MA38399B2/fr unknown
- 2014-03-14 MY MYPI2015002299A patent/MY186048A/en unknown
- 2014-03-14 CA CA3147180A patent/CA3147180C/en active Active
- 2014-03-14 PT PT147194724T patent/PT2968173T/pt unknown
- 2014-03-14 SG SG10201706656RA patent/SG10201706656RA/en unknown
- 2014-03-14 RS RS20201513A patent/RS61215B1/sr unknown
- 2014-03-14 JP JP2016502336A patent/JP6498658B2/ja active Active
- 2014-03-14 ES ES14720369T patent/ES2750676T3/es active Active
- 2014-03-14 MX MX2015012429A patent/MX2015012429A/es unknown
- 2014-03-14 SM SM20200685T patent/SMT202000685T1/it unknown
- 2014-03-14 ES ES14719472T patent/ES2837038T3/es active Active
- 2014-03-14 PT PT147203699T patent/PT2970123T/pt unknown
- 2014-03-14 AP AP2015008789A patent/AP2015008789A0/xx unknown
- 2014-03-14 HR HRP20191728 patent/HRP20191728T1/hr unknown
- 2014-03-14 EP EP14720369.9A patent/EP2970123B2/en active Active
- 2014-03-14 CN CN201810812212.8A patent/CN108785265B/zh active Active
- 2014-03-14 DK DK14720369.9T patent/DK2970123T3/da active
- 2014-03-14 TW TW103109296A patent/TWI667026B/zh active
- 2014-03-14 CN CN201480014897.1A patent/CN105120844A/zh active Pending
- 2014-03-14 US US14/210,713 patent/US9951015B2/en active Active
- 2014-03-14 UA UAA201509685A patent/UA117011C2/uk unknown
- 2014-03-14 UY UY0001035449A patent/UY35449A/es active IP Right Grant
- 2014-03-14 ME MEP-2019-283A patent/ME03566B/me unknown
- 2014-03-14 EA EA201591728A patent/EA031185B1/ru unknown
- 2014-03-14 HU HUE14719472A patent/HUE052355T2/hu unknown
- 2014-03-14 MA MA44637A patent/MA44637B1/fr unknown
- 2014-03-14 MX MX2015012414A patent/MX363347B/es unknown
- 2014-03-14 SI SI201431724T patent/SI2968173T1/sl unknown
- 2014-03-14 NZ NZ711225A patent/NZ711225A/en unknown
- 2014-03-14 AU AU2014239995A patent/AU2014239995B2/en active Active
- 2014-03-14 HU HUE14720369A patent/HUE046285T2/hu unknown
- 2014-03-14 WO PCT/US2014/027146 patent/WO2014152270A1/en not_active Ceased
- 2014-03-14 PL PL14719472T patent/PL2968173T3/pl unknown
- 2014-03-14 JP JP2016502348A patent/JP6783138B2/ja active Active
- 2014-03-14 SI SI201431358T patent/SI2970123T1/sl unknown
- 2014-03-14 MY MYPI2019004869A patent/MY204971A/en unknown
- 2014-03-14 PH PH1/2019/500176A patent/PH12019500176B1/en unknown
- 2014-03-14 SG SG11201507258PA patent/SG11201507258PA/en unknown
- 2014-03-14 LT LTEP14719472.4T patent/LT2968173T/lt unknown
- 2014-03-14 HK HK16106250.4A patent/HK1218080A1/zh unknown
- 2014-03-14 LT LT14720369T patent/LT2970123T/lt unknown
- 2014-03-14 BR BR112015023417-8A patent/BR112015023417B1/pt active IP Right Grant
- 2014-03-14 PL PL14720369T patent/PL2970123T3/pl unknown
- 2014-03-14 WO PCT/US2014/027104 patent/WO2014152236A1/en not_active Ceased
- 2014-03-14 KR KR1020157025283A patent/KR102374159B1/ko active Active
- 2014-03-14 US US14/773,436 patent/US9988354B2/en active Active
- 2014-03-14 BR BR112015022857-7A patent/BR112015022857B1/pt active IP Right Grant
- 2014-03-14 EP EP20201011.2A patent/EP3821882A1/en active Pending
- 2014-03-14 RU RU2015143643A patent/RU2663663C2/ru active
- 2014-03-14 HR HRP20201967TT patent/HRP20201967T1/hr unknown
- 2014-03-14 SM SM20190563T patent/SMT201900563T1/it unknown
- 2014-03-14 CN CN201480018405.6A patent/CN105209437B/zh active Active
- 2014-03-14 AU AU2014240049A patent/AU2014240049C1/en active Active
- 2014-03-14 DK DK14719472.4T patent/DK2968173T3/da active
- 2014-03-14 AR ARP140101155A patent/AR095542A1/es not_active Application Discontinuation
- 2014-03-16 JO JOP/2014/0114A patent/JOP20140114B1/ar active
-
2015
- 2015-08-24 IL IL240788A patent/IL240788B/en active IP Right Grant
- 2015-08-31 TN TN2015000380A patent/TN2015000380A1/en unknown
- 2015-09-03 IL IL24108915A patent/IL241089B/en active IP Right Grant
- 2015-09-08 PH PH12015501998A patent/PH12015501998A1/en unknown
- 2015-09-11 MX MX2021001231A patent/MX2021001231A/es unknown
- 2015-09-14 CL CL2015002708A patent/CL2015002708A1/es unknown
- 2015-09-14 SA SA515361088A patent/SA515361088B1/ar unknown
- 2015-10-13 CR CR20150549A patent/CR20150549A/es unknown
-
2018
- 2018-03-20 US US15/926,411 patent/US10421726B2/en active Active
- 2018-04-26 US US15/963,529 patent/US20180312469A1/en not_active Abandoned
- 2018-11-15 JP JP2018214801A patent/JP6689942B2/ja active Active
-
2019
- 2019-09-23 US US16/579,360 patent/US11384053B2/en active Active
- 2019-10-15 CY CY20191101080T patent/CY1122695T1/el unknown
- 2019-11-14 US US16/684,216 patent/US20200079736A1/en not_active Abandoned
-
2020
- 2020-04-08 JP JP2020069487A patent/JP6966590B2/ja active Active
- 2020-07-02 US US16/920,144 patent/US11472773B2/en active Active
- 2020-07-02 US US16/920,155 patent/US20200331859A1/en not_active Abandoned
- 2020-12-15 CY CY20201101184T patent/CY1123633T1/el unknown
-
2021
- 2021-09-24 US US17/448,833 patent/US11958809B2/en active Active
- 2021-10-21 JP JP2021172324A patent/JP7174132B2/ja active Active
-
2022
- 2022-06-08 US US17/806,033 patent/US11884630B2/en active Active
- 2022-09-08 US US17/930,695 patent/US20230044617A1/en not_active Abandoned
-
2023
- 2023-06-01 AR ARP230101396A patent/AR129504A2/es unknown
- 2023-11-27 US US18/520,156 patent/US12221417B2/en active Active
- 2023-12-06 US US18/531,424 patent/US12275704B2/en active Active
-
2024
- 2024-01-24 US US18/421,849 patent/US20240317687A1/en active Pending
- 2024-12-20 US US18/990,483 patent/US20250243163A1/en active Pending
-
2025
- 2025-01-17 US US19/029,911 patent/US20250376444A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129504A2 (es) | Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2015017345A (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2017002028A (es) | Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7). | |
| MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
| PH12016500756A1 (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX2017010735A (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| PE20160930A1 (es) | Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso. | |
| WO2014197093A3 (en) | All water-based nanopatterning | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| NZ714558A (en) | Formulation comprising a hypolipidemic agent | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
| BR112015023351A2 (pt) | forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| PL408608A1 (pl) | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| UY37444A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso |